For the year ending 2025-12-31, KLRS had $96,914K increase in cash & cash equivalents over the period. -$38,570K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -43,438 |
| Depreciation expense | 13 |
| Stock-based compensation expense | 1,936 |
| Change in fair value of derivative liabilities (including 1,165 and 2,039 for a related party) | 1,229 |
| Change in fair value of tranche liability (including 331 and 19,064 for a related party) | 365 |
| Non-cash interest expense (including 1,384 and 2,656 for a related party) | 1,443 |
| Non-cash operating lease expense | -53 |
| Net amortization of premiums and accretion of discounts on marketable securities | 399 |
| Loss on extinguishment and on issuance of convertible promissory notes (including 169 and 34,692 for a related party) | -186 |
| Prepaid expense and other current assets | -1,810 |
| Other non-current assets | 355 |
| Accounts payable | -88 |
| Accrued expenses and other current liabilities (including 16 and 0 for a related party) | 2,144 |
| Operating lease liabilities | -81 |
| Net cash used in operating activities | -38,370 |
| Purchases of short-term marketable securities | 34,523 |
| Maturities of short-term marketable securities | 15,000 |
| Purchase of property and equipment | 200 |
| Net cash used in investing activities | -19,723 |
| Proceeds from issuance of common stock in private placement | 42,000 |
| Proceeds from issuance of pre-funded warrants in private placement | 8,000 |
| Payment of issuance costs | 1,669 |
| Proceeds from the issuance of convertible promissory notes (including 3,402 and 19,041 from a related party), net of issuance costs | 7,500 |
| Cash acquired in connection with the merger | 102,113 |
| Payment of deferred transaction costs and issuance costs | 2,937 |
| Net cash provided by financing activities | 155,007 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 96,914 |
| Cash and cash equivalents and restricted cash, at beginning of the period | 1,639 |
| Cash and cash equivalents and restricted cash, at end of the period | 98,553 |
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)